Download full-text PDF

Source
http://dx.doi.org/10.1002/cncy.22760DOI Listing

Publication Analysis

Top Keywords

hpv persistence
4
persistence cervical
4
cervical surgical
4
surgical excision
4
excision high-grade
4
high-grade cervical
4
cervical lesions
4
cervical
2
hpv
1
surgical
1

Similar Publications

Cervical cancer ranks as the fourth most common cancer among women globally, posing a significant mortality risk. Persistent infection with high-risk human papillomavirus (HPV) is the primary instigator of cervical cancer development, often alongside co-infection with other viruses, precipitating various malignancies. This study aimed to explore recent biotechnological advances in understanding HPV infection dynamics, host interactions, and its role in oncogenesis.

View Article and Find Full Text PDF

Plantar warts, or verrucae plantares, are skin lesions on the soles of the feet caused by human papillomavirus (HPV). These warts are prevalent and affect up to 33% of children and 3.5% of adults.

View Article and Find Full Text PDF

Human papillomavirus (HPV) is a key factor in gynecological oncology. This narrative review investigates the complex connection between HPV and various gynecological cancers. For a comprehensive exploration, we examined the association between persistent HPV infection and cervical cancer and its global prevalence.

View Article and Find Full Text PDF

Clinical Benefit of a Conservative Treatment for High-Risk Human Papillomavirus Lesions in Patients with HIV.

AIDS Res Hum Retroviruses

January 2025

Servicio de Ginecología y Obstetricia, Hospital Universitario Torrecárdenas, GAEPI-VPH (Grupo Andaluz para el Estudio y la Prevención de la Infección por VPH), Almería, Spain.

Infection with Human immunodeficiency virus (HIV) shows a higher risk of infection by Human papillomavirus (HPV). We aim to provide evidence about the effect of a -based vaginal gel (Papilocare®) for treating HPV in women with HIV. Women ≥25 years coinfected by endocervical HPV and with low-grade abnormal cervicovaginal cytology were treated for 6 months with Papilocare® in this observational, prospective, non-controlled pilot study.

View Article and Find Full Text PDF

Background: Second-line treatment options for persistent, recurrent or metastatic (r/m) cervical cancer are limited. We investigated the safety, efficacy, and immunogenicity of the therapeutic DNA-based vaccine VB10.16 combined with the immune checkpoint inhibitor atezolizumab in patients with human papillomavirus (HPV)16-positive r/m cervical cancer.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!